CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project develops engineered bacteria that can be controlled to deliver therapeutic agents specifically to tumors. By utilizing a synthetic receptor platform, the bacteria can release treatment in response to dietary molecules, enhancing the precision of cancer therapies.
Engineered microbes are attractive platforms for the diagnosis and treatment of several diseases.
For example, bacteria can selectively target tumors and are ideal vehicles for in situ delivery of therapeutic agents.However, as of today, no engineered living bacterial therapeutics in clinical trials have the ability for conditional control of therapeutic activity.
This lack of reliable control over the timing and dosage of effector molecule production limits the specificity, safety, and efficacy…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
